Breaking News Instant updates and real-time market news.

CRSP

Crispr Therapeutics

$30.29

0.485 (1.63%)

, NTLA

Intellia Therapeutics

$13.06

0.25 (1.95%)

13:10
02/08/19
02/08
13:10
02/08/19
13:10

University of California to be awarded key CRISPR patent, STAT reports

The University of California will be awarded a "foundational" CRISPR-Cas9 patent that has been at the center of a drawn out legal battle, reported STAT's Sharon Begley, citing documents posted by the U.S. Patent and Trademark Office. The Fly notes that CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA) and Caribou Biosciences previously announced on September 10, 2018 that the U.S. Court of Appeals for the Federal Circuit affirmed the decision by the U.S. Patent and Trademark Office's Patent Trial and Appeal Board in an interference proceeding relating to CRISPR/Cas9 genome editing technology. The interference was requested by the Regents of the University of California, the University of Vienna and Dr. Emmanuelle Charpentier, co-owners of foundational intellectual property relating to CRISPR/Cas9 genome engineering, against the Broad Institute, Harvard University and the Massachusetts Institute of Technology. Editas Medicine (EDIT) is another company pursuing CRISPR-based therapies. Reference Link

CRSP

Crispr Therapeutics

$30.29

0.485 (1.63%)

NTLA

Intellia Therapeutics

$13.06

0.25 (1.95%)

CRSP Crispr Therapeutics
$30.29

0.485 (1.63%)

01/28/19
GSCO
01/28/19
DOWNGRADE
Target $40
GSCO
Neutral
Crispr Therapeutics downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Salveen Richter downgraded Crispr Therapeutics to Neutral and cut his price target for the shares to $40 from $78.
01/28/19
GSCO
01/28/19
DOWNGRADE
Target $40
GSCO
Neutral
Goldman downgrades Crispr Therapeutics to Neutral on lack of 2019 catalysts
Goldman Sachs analyst Salveen Richter downgraded Crispr Therapeutics to Neutral and cut his price target for the shares to $40 from $78. The stock closed Friday up 91c to $33.20. The analyst, while acknowledging Crispr "is a pioneer in the field of CRISPR/Cas9 gene editing," moves to the sidelines with the respect to the stock as he sees a lack of catalysts until the end of 2019. Further, he believes Bluebird Bio's (BLUE) gene therapy LentiGlobin has set a "high clinical hurdle and first-mover advantage" in transfusion-dependent beta-thalassemia and sickle cell disease. In addition, the allogeneic or "off-the-shelf" CAR T cancer field is getting "increasingly crowded with evolving timelines," Richter tells investors in a research note.
02/07/19
PIPR
02/07/19
NO CHANGE
Target $75
PIPR
Overweight
Crispr Therapeutics sell-off 'unfounded,' Overweight reiterated at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $75 price target on Crispr Therapeutics (CRSP). In a research note to investors, Tenhoff noted that Crispr and the broader gene editing space are selling off in reaction to Sangamo's (SGMO) presentation of interim data from the first in vivo gene editing study at WORLD Symposium 2019, which showed no meaningful changes in IDS or GAG levels in six patients after 23 weeks. Tenthoff says he does not see read-through to Crispr and that he believes CTX001 ex vivo approach and biological rational of targeting fetal hemoglobin de-risk and differentiate Crispr and that he is a buyer on "unfounded" sell-off in shares.
02/07/19
BTIG
02/07/19
INITIATION
BTIG
Buy
Crispr Therapeutics initiated with a Buy at BTIG
BTIG analyst Amanda Murphy initiated Crispr Therapeutics with a Buy rating and $43 price target. Murphy sees Crispr as a front runner in the allogeneic pack, with its budding CAR-T pipeline. The analyst believes CTX001 represents under 5% of that price target, while the CAR-T franchise represents roughly 35%, and that the largest contribution comes from the value of the company's underlying platform, which accounts for slightly under 50% of the price target.
NTLA Intellia Therapeutics
$13.06

0.25 (1.95%)

11/02/18
WEDB
11/02/18
DOWNGRADE
Target $20
WEDB
Neutral
Intellia Therapeutics downgraded to Neutral from Outperform at Wedbush
Wedbush analyst David Nierengarten downgraded Intellia Therapeutics to Neutral from Outperform and lowered his price target to $20 from $36 as development delays push out initiation of the company's first clinical trial likely another six months to sometime in 2020. In a research note to investors, the analyst says he overall continues to see broad utility and value for the company's IP and CRISPR/Cas9 gene editing and lipid nanoparticle delivery capabilities, and is "encouraged" by recent LNP delivery enhancements and LNP-AAV hybrid activity in preclinical models; however, with a lack of meaningful catalysts over the next 12 months, Nierengarten suggests moving to the sidelines in the near term until there is more clarity around and approach the company's first IND filing.
11/27/18
LEER
11/27/18
INITIATION
Target $23
LEER
Outperform
Intellia Therapeutics initiated with an Outperform at Leerink
Leerink analyst Mani Foroohar initiated Intellia Therapeutics with an Outperform rating and a price target of $23.
11/27/18
LEER
11/27/18
INITIATION
LEER
Leerink initiates select Genetic Medicine names on increasing regulatory clarity
Leerink analyst Mani Foroohar initiated select Genetic Medicine stocks, stating that the field is "is rich with companies developing drugs" to treat rare diseases and that he is increasingly more bullish on "innovation velocity and increasing regulatory clarity in the sector. Based on his "balanced view of pricing dynamics", the analyst issues an Outperform rating on Wave Life Sciences (WVE), Rocket Pharmaceuticals (RCKT), Intellia Therapeutics (NTLA), Eidos Therapeutics (EIDX), Dicerna (DRNA) and Bluebird Bio (BLUE). The analyst likes Wave Life Sciences as a pure play on Oligotherapeutics and its stereopure chemistry platform as a differentiated approach to oligo drug design. Foroohar is positive on Rocket Pharma's lead assets in gene therapies for Fanconi Anemia and Leukocyte Adhesion Deficiency-I "which will likely be the company's first potential approved product." The analyst is positive on Intellia Therapeutics' "robust balance sheet to support development, trading at a material discount to closest comps peers". For Eidos, the analyst cites the prospects of its drug candidate for TTR amyloidosis currently in a placebo-controlled Phase 2 study that may offer a competitive profile relative to Pfizer's (PFE) tafamidis. For Dicerna, Foroohar notes that its DCR-PHXC "is an RNAi therapeutic that targets lactate dehydrogenase A for the treatment of all subtypes of Primary Hyperoxaluria vs. competitor Alnylam's (ALNY) lumasiran, which only treats PH Type 1. For Bluebird Bio, the analyst is positive on its position as a "leader in ex vivo gene therapy, with four programs with visibility towards near-term regulatory approval". Foroohar initiates Avrobio (AVRO), Alnylam (ALNY), and Ionis Pharmaceuticals (IONS) with Market Perform rating based on competitive launches for their products along with "mixed" early signs of their results. The analyst also rates Regenxbio (RGNX) at underperform, saying that its "current valuation more than accounts for robust royalty streams from sales in spinal muscular atrophy" and other partnered assets.
02/07/19
BTIG
02/07/19
INITIATION
BTIG
Buy
Intellia Therapeutics initiated with a Buy at BTIG
BTIG analyst Amanda Murphy initiated Intellia Therapeutics with a Buy rating and $20 price target. Murphy said Intellia's in vivo pipeline is the "most well-characterized" of the public gene editing companies, and she sees upside from wholly-owned programs in oncology and CNS.

TODAY'S FREE FLY STORIES

DDAIF

Daimler AG

$0.00

(0.00%)

18:46
07/15/19
07/15
18:46
07/15/19
18:46
Initiation
Daimler AG initiated  »

Daimler AG initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PUGOY

Peugeot

$0.00

(0.00%)

18:46
07/15/19
07/15
18:46
07/15/19
18:46
Initiation
Peugeot initiated  »

Peugeot initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCAU

Fiat Chrysler

$14.18

0.045 (0.32%)

18:45
07/15/19
07/15
18:45
07/15/19
18:45
Initiation
Fiat Chrysler initiated  »

Fiat Chrysler initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

TGI

Triumph Group

$23.07

-0.22 (-0.94%)

18:42
07/15/19
07/15
18:42
07/15/19
18:42
Hot Stocks
Triumph Group selected by leading airline as MRO provider »

Triumph Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 31

    Jul

TRQ

Turquoise Hill

$1.07

-0.02 (-1.83%)

18:32
07/15/19
07/15
18:32
07/15/19
18:32
Hot Stocks
Turquoise Hill reports Q2 copper output 39.2KT, down 0.6% from last year »

Reports Q2 Gold output…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RIO

Rio Tinto

$61.50

0.77 (1.27%)

18:29
07/15/19
07/15
18:29
07/15/19
18:29
Hot Stocks
Rio Tinto cuts FY19 Pilbara ore shipments view to 320M-330M tons »

Prior view was 333M-343M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

RIO

Rio Tinto

$61.50

0.77 (1.27%)

18:28
07/15/19
07/15
18:28
07/15/19
18:28
Hot Stocks
Rio Tinto report Q2 Pilbara iron ore output 79.7M tons, down 7% from last year »

Reports Q2 Pilbara iron…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

VMW

VMware

$172.22

2.48 (1.46%)

18:24
07/15/19
07/15
18:24
07/15/19
18:24
Hot Stocks
VMware: We have momentum across the board »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

CGIX

Cancer Genetics

$0.17

-0.0059 (-3.35%)

, IDXG

Interpace Diagnostics

$0.70

-0.0071 (-1.01%)

18:21
07/15/19
07/15
18:21
07/15/19
18:21
Conference/Events
Interpace Diagnostics to hold a conference call »

Conference call to…

CGIX

Cancer Genetics

$0.17

-0.0059 (-3.35%)

IDXG

Interpace Diagnostics

$0.70

-0.0071 (-1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

17:55
07/15/19
07/15
17:55
07/15/19
17:55
Conference/Events
Stephens business services analyst to hold a group dinner »

Group Dinner Meeting to…

EYEN

Eyenovia

$2.89

0.04 (1.40%)

17:51
07/15/19
07/15
17:51
07/15/19
17:51
Hot Stocks
Eyenovia CEO buys 233.8K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ET

Energy Transfer LP

$14.91

0.09 (0.61%)

17:38
07/15/19
07/15
17:38
07/15/19
17:38
Periodicals
Energy Transfer considering sale of 33% Rover pipeline stake, Bloomberg says »

Energy Transfer (ET) is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INNT

Innovate Biopharmaceuticals

$1.12

0.02 (1.82%)

17:37
07/15/19
07/15
17:37
07/15/19
17:37
Hot Stocks
Innovate Biopharmaceuticals gives corporate update, undertakes CEO search effort »

Innovate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LAMR

Lamar Advertising

$80.70

-0.31 (-0.38%)

17:36
07/15/19
07/15
17:36
07/15/19
17:36
Hot Stocks
Lamar Advertising to acquire Ashby Street Outdoor Holdings »

Ashby Street Outdoor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

LMT

Lockheed Martin

$367.65

-1.81 (-0.49%)

17:24
07/15/19
07/15
17:24
07/15/19
17:24
Hot Stocks
Lockheed Martin awarded $492.11M Army contract for M142 launchers »

Lockheed Martin was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

EGHT

8x8, Inc.

$25.62

-0.24 (-0.93%)

, FIVN

Five9

$48.00

-5.53 (-10.33%)

17:15
07/15/19
07/15
17:15
07/15/19
17:15
Conference/Events
Stephens communications analysts to hold an analyst/industry conference call »

Communications Analysts,…

EGHT

8x8, Inc.

$25.62

-0.24 (-0.93%)

FIVN

Five9

$48.00

-5.53 (-10.33%)

LOGM

LogMeln

$76.57

0.41 (0.54%)

RNG

RingCentral

$123.31

0.34 (0.28%)

WORK

Slack Technologies

$34.78

1.04 (3.08%)

TWLO

Twilio

$145.36

3.185 (2.24%)

VG

Vonage

$12.79

-0.2 (-1.54%)

ZM

Zoom Video

$99.76

6.465 (6.93%)

GOOG

Alphabet

$1,150.39

5.84 (0.51%)

MSFT

Microsoft

$138.94

0.08 (0.06%)

AMZN

Amazon.com

$2,021.00

10.38 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 18

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 30

    Jul

  • 31

    Jul

  • 01

    Aug

  • 06

    Aug

  • 08

    Aug

  • 08

    Aug

  • 27

    Oct

  • 13

    Nov

WTI

W&T Offshore

$4.83

0.13 (2.77%)

17:08
07/15/19
07/15
17:08
07/15/19
17:08
Hot Stocks
W&T Offshore CEO buys 100K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRT

StarTek

$7.10

0.04 (0.57%)

17:08
07/15/19
07/15
17:08
07/15/19
17:08
Syndicate
Breaking Syndicate news story on StarTek »

StarTek files $100M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

VTVT

vTv Therapeutics

$1.37

(0.00%)

17:08
07/15/19
07/15
17:08
07/15/19
17:08
Hot Stocks
vTv Therapeutics jumps 20% after saying it will make presentation at AAIC »

vTv Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JBHT

J.B. Hunt

$92.50

-0.45 (-0.48%)

16:53
07/15/19
07/15
16:53
07/15/19
16:53
Hot Stocks
Breaking Hot Stocks news story on J.B. Hunt »

J.B. Hunt up over 6% at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jul

  • 26

    Aug

  • 13

    Nov

ARW

Arrow Electronics

$68.82

-0.15 (-0.22%)

16:52
07/15/19
07/15
16:52
07/15/19
16:52
Hot Stocks
Breaking Hot Stocks news story on Arrow Electronics »

Arrow Electronics down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBNK

United Financial

$14.02

-0.1 (-0.71%)

16:45
07/15/19
07/15
16:45
07/15/19
16:45
Hot Stocks
Breaking Hot Stocks news story on United Financial »

United Financial trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

TRWH

Twin River Worldwide

$28.90

-0.08 (-0.28%)

16:44
07/15/19
07/15
16:44
07/15/19
16:44
Hot Stocks
Standard General to tender 13M shares from Twin River Worldwide »

Twin River Worldwide…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HQY

HealthEquity

$70.29

-1.38 (-1.93%)

16:44
07/15/19
07/15
16:44
07/15/19
16:44
Hot Stocks
HealthEquity director Robert Selander buys 610K in company shares »

HealthEquity director…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSS

TSYS

$133.45

1.26 (0.95%)

, GPN

Global Payments

$165.94

1.69 (1.03%)

16:39
07/15/19
07/15
16:39
07/15/19
16:39
Hot Stocks
Global Payments establishes new credit agreement to support merger with TSYS »

Global Payment (GPN)…

TSS

TSYS

$133.45

1.26 (0.95%)

GPN

Global Payments

$165.94

1.69 (1.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.